• 최신업적링크:

 

1) Google Scholar

 

https://scholar.google.co.kr/citations?hl=en&user=D5fe7zoAAAAJ&view_op=list_works&sortby=pubdate

 

2) ResearchGate

 

https://www.researchgate.net/profile/Hae_Suh

​

 

​

•  Publications

 

64. Kim S, Han S, Kim H, and Suh HS. Cost-effectiveness and value of information of cabozantinib treatment for patients with advanced renal cell carcinoma after failure of prior therapy in South Korea. Applied Health Economics and Health Policy. 2021. doi: 10.1007/s40258-021-00640-w. Online ahead of print. (2021.03.02).

63. Kim H, Choi JY, Hong M, and Suh HS. Traditional medicine treatment of the common cold for adults in Korea: A nationwide population-based study. Integrative Medicine Research. 2021;10(1):100458 (2021.03.01).

62. Kim S, Kim E, and Suh HS. Cost-effectiveness of an opioid abuse-prevention program using the narcotics information management system in South Korea. Value in Health. 2021;24(2): 174-181. (2021.02.08).

61. Bang OY, On YK, Lee MY, Jang SW, Han S, Han S, Won MM Park YJ, Lee MJ, Choi HY, Kang S, Suh HS, and Kim YH. The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. PLOS ONE. 2020;15(11): e0242922. (2020.11.30).

60. Choi K, Han S, and Suh HS. Emergency department visits and hospitalizations for emergent asthmatic symptoms from 2014 to 2016: Cross-sectional study in Korea. BMJ Open. 2020;10:e036237.(2020.09.03).

59. Kim H and Suh HS. Effects of a safety letter on metoclopramide use in Korea: An interrupted time-series analysis. Risk Management and Healthcare Policy. 2020;13:1335-1341. (2020.08.24).

58. Kim H, Park KS, Yoo JE, Kim S, Han S, and Suh HS. Cultural adaptation and validation of the Korean version of the iMTA productivity cost questionnaire. Healthcare. 2020;8(184):1-10. (2020.06.24).

57. Kim KS, Suh, SY, Lim JM, Lee J, Koh Y, and Suh HS. Assessment of economic benefit of clinical pharmacy services in oncology. Yakhak Hoeji. 2020;64(3):219-25.(2020.06).

56. Park S, Kim H, and Suh HS. Cost-benefit analysis for expanding insurance coverage of dental scaling to adolescents in South Korea. The Korean Journal of Health Economics and Policy. 2020;26(2):1-23. (2020.06).

55. Park S and Suh HS. A review of current drugs for COVID-19. Journal of the Health Technology Assessment. 2020;8(1): 20-25. (2020.06).

54. Woo HL, Ji HR, Kim S, Suh HS, Kim KI, Lee MJ, and Park KS. Efficacy and safety of herbal medicine (Dangguijagyag-san) for primary dysmenorrhea: study protocol for a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial. Integrative Medicine Research. 2020;9(2):100394. (2020.04.20).

53. Kim S, Han S, Rane PR, Qian Y, Zhao Z, and Suh HS. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea. PLOS ONE. 2020;15(1): e0228472. (2020.01).

52. Kim S and Suh HS. Current status of parkinsonism-related adverse events and associated drugs in Korea. Journal of Patient Safety. 2019;15(4):e56-e59.(2019.12.)

51. Lee CH, Kim S, and Suh HS. Current status and factors affecting prescription of gastrointestinal motility drugs in patients with Parkinson’s disease. Yakhak Hoeji. 2019;63(6):333-340.(2019.12).

50. Han S and Suh HS. Hospitalization through Emergency Department Visit in Patients with Asthma: Association Rule Mining Approach. Journal of the Health Technology Assessment. 2019;7(2): 134-138. (2019.12).

49. Kim S, Park SJ, Byun SJ, Park KH, and Suh HS. Incremental economic burden associated with exudative age-related macular degeneration: A population-based study. BMC Health Services Research. 2019;19:828-8

48. Han S and Suh HS. Types of exacerbation, case-fatality and medical costs in patients with severe and uncontrolled asthma. Yakhak Hoeji. 2019;63(5):292-296.(2019.10.31).

47. Han S, Kim S, Kim H, Shin HW, Na KS, and Suh HS. Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea. BMC Public Health. 2019;19:1328-1337. (2019.10.22).

46. Shin S, Jang BH, Park SH, Lee JW, Chae MS, Kim N, Suh HS, Han S, Min SY, Baek SK, Lim YJ, and Hwang DS. Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibit or-induced arthralgia of postmenopausal breast cancer stage I–III patients: study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial. Medicine. 2019;98(38):e17260.(2019.09.01).

45. Kim S, Cheon SM, and Suh HS. Association Between Drug Exposure and Occurrence of Parkinsonism in Korea: A Population-Based Case-Control Study. Annals of Pharmacotherapy. 2019;53(11):1102-1110. (2019.09.11).

44. Kim H, Kim S, Han S, Rane PP, Fox KM, Qian Yi, and Suh HS. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19:1112-1123. (2019.08.14).

43. Han S, Park KS, Lee H, Zhu X, Lee JM, Suh HS. Transcutaneous electrical nerve stimulation (TENS) for pain control in women with primary dysmenorrhoea (Protocol). Cochrane Database of Systematic Reviews. 2019, Issue 5.

42. Kim H, Kim S, and Suh HS. Current state of medication error in Korea: Analysis of medication injury relief in Korea Consumer Agency. Journal of the Health Technology Assessment. 2019;7(1):88-93. (2019.06).

41. Han S, Kim S, Kim H, and Suh HS. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea. Current Medical Research and Opinion. 2019;35(9):1597-1605. (2019.05.16).

40. Han S, Jang BH, Suh HS, and Hwang DS. Complementary medicine use and costs in patients with breast cancer who experienced treatment-related side effects: A cross-sectional survey in Korea. Complementary Therapies in Medicine. 2019;44:210-217. (2019.06).

39. Shin S, Jang BH, Suh HS, Park SH, Lee JW, Yoon SW, Kong M, Lim YJ, and Hwang DS. Effectiveness, safety, and economic evaluation of topical application of a herbal ointment, Jaungo, for radiation dermatitis after breast conserving surgery in patients with breast cancer (GREEN study): Study protocol for a randomized controlled trial. Medicine. 2019;98(15):e15174. (2019.04).

38. Han S, Kim H, and Suh HS. The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65. PLOS ONE. 2019;14(4):e0214666. (2019.04).

37. Jung SY, Suh HS, and Kwon JW. Drug Holiday Patterns and Bisphosphonate-Related Osteonecrosis of the Jaw. Oral Diseases. 2019;25(2):471-480. (2019.02).

36. Kim H, Kwon MS, Oh HJ and Suh HS. Clinical and economics effects of pharmaceutical care: a systematic review. Journal of Korean Academy of Social & Managed Care Pharmacy. 2019;7(1):39-51.(2019.02).

35. Cho H, Myung J, Suh HS, and Kang HY. Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis. Osteoporosis International. 2018;29(10):2163-2170. (2018.10.)

34. Kim S, Kim H, Kim E, Han S, Rane PP, Fox KM, Zhao Z, Qian Yi, and Suh HS. Utilization Patterns of Lipid-lowering Therapies in Patients with Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea. Clinical Therapeutics. 2018;40(6):940-951. (2018.06).

33. Suh HS, Kim JA, and Lee IH. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study. BMC Health Services Research. 2018;18:429-439. (2018.06).

32. Son JS, Han S, Kim H, Kim S, and Suh HS. Long-Term Oral Corticosteroid Use and Related Infections in Elderly Patients with Severe Asthma. Journal of the Health Technology Assessment. 2018;6(1):50-56. (2018.06).

31. Kim S, Kim H, and Suh HS. Combination Therapy of BRAF Inhibitors for Advanced Melanoma with BRAF V600 Mutation: A Systematic Review and Meta-Analysis. Journal of Dermatological Treatment. 2018;29(3):314-321. (2018.04).

30. Lee IY, Kang HY, Suh HS, Lee S, Oh ES, and Jeong H. Awareness and attitude of the public toward personalized medicine in Korea. PLOS ONE. 2018 Feb 16;13(2):e0192856 (2018.02).

29. Park SY, Park EJ, Suh HS, Ha D, and Lee EK. Development of a transformation model to derive general population-based utility: Mapping the pruritus-visual analog scale (VAS) to the EQ-5D utility. Journal of Evaluation in Clinical Practice. 2017;23(4):755-761. (2017.08).

28. Kim H, Choi HD, Kim S, Han S, Lee IH, and Suh HS. Types of Medication Error to Be Used in Korea. Journal of the Health Technology Assessment. 2017;5(1):31-41. (2017.06).

27. Yoon JH, Suh HS, and Je NK. The students’ evaluation of practice sites and preceptors in pharmacy experiential education. Korean Journal of Clinical Pharmacy. 2017;27(2):69-76. (2017.06).

26. Kim KI, Suh HS, Kwak A, Kim S, Han N, Lee E, and Oh JM. Development and Validation of a Modified Korean Version of the Pharmacy Services Questionnaire (PSQ-K) for the Quality Assessment of Community Pharmacy Services. PLOS ONE. 2017 April 25;12(4):e0174004 (online). (2017.04).

25. Park KS, Park KI, Suh HS, Hwang DS, Jang JB, and Lee JM. The efficacy and safety of acupuncture on serum leptin levels in obese patients: a systematic review and meta-analysis. European Journal of Integrative Medicine. 2017;11:45-52. (2017.04).

24. Han S, Jang BH, Hwang DS, and Suh HS. Experiences of treatment-related side effects and supportive care with Korean medicine in women with breast cancer – a focus group study. The Journal of Oriental Obstetrics and Gynecology. 2017;30(1):085-094. (2017.03).

23. Yoon J, Kim S, Suh HS. The effect of a change in reimbursement criteria on the utilization of tumor necrosis factor-α inhibitors in elderly patients with rheumatoid arthritis in Korea. The Korean Journal of Health Economics and Policy. 2016;22(4):79-99. (2016.12.)

22. Kim S, Han S, Suh HS. The analysis of definition and types for medication error used in foreign countries. Journal of the Health Technology Assessment. 2016;4(2):35-43. (2016.12).

21. Jung SY, Sohn HS, Park EJ, Suh HS, Park JW, and Kwon JW. Oral bisphosphonates and upper gastrointestinal cancer risks in Asians with osteoporosis: A nested case-control study using national retrospective cohort sample data from Korea. PLOS ONE. 2016;11(3):e0150531. (March 3, 2016, online).

20. Choi WJ, Yim E, Kim TH, Suh HS, Choi KC, and Chung W. Analysis of Factors Related to the Prescription of Antibiotics for the Acute Upper Respiratory Infection. Health Policy and Management. 2015;25(4):256-263.(2015.12).

19. BR Lee and Suh HS. Citizen participation in the decision-making process for drug reimbursement: Experts’ points of view involved in this process. The Korean Journal of Health Economics and Policy. 2015;21(4):21-41. (2015.12).

18. Kwon JW, Park EJ, Jung SY, Sohn HS, Ryu H, and Suh HS. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study. Journal of Dental Research. 2015;94(9):212S-219S. (2015.09).

17. Lim S, Lee KH, Suh HS, Bae KH. To whom do bureaucrats need to respond? Two faces of civil society in health policy. Social Science & Medicine. 2014;123:269-277 (2014.12).

16. Seo EY, An SH, Cho JH, Suh HS, Park SH, Gwak H, Kim YL, Ha H. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Peritoneal Dialysis International.2014;34(7):724-731 (2014.11-12).

15. Suh HS, Kang HY, Kim JK, and Shin E. Effect of health insurance type on health care utilization in patients with hypertension: a National Health Insurance database study in Korea. BMC Health Services Research.2014;14:570-582. (2014.11).

14. Suh HS and Kang HY. Educational demands of pharmacists working in the pharmaceutical industry under the reformed 6-year pharmacy education system in Korea. Pharmacy Education. 2014;14(1):76-80 (2014.07).[SCOPUS]

13. Suh HS and Lee B. Citizen participation in the healthcare decision-making process: review of real cases. Journal of the Health Technology Assessment. 2014;2(1):19-25.

12. Suh HS, Song HJ, Jang EJ, Kim JS, Choi DH, and Lee SM. Use of drug-eluting stents versus bare-metal stents in Korea: A cost-minimization analysis using population data. Journal of Preventive Medicine and Public Health. 2013;46(4):201-209 (2013.08).

11. Lee SM, Kim G, Ahn J, Suh HS, and Heo DS. Factors influencing decision-making on therapeutic interventions in terms of safety and efficacy. International Journal of Technology Assessment in Health Care. 2013;29(3):331-335 (2013.07).

10. Godman B, Campbell S, Suh HS, Finlayson AE, Bennie M, and Gustafsson LL. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. Journal of the Health Technology Assessment. 2013;1(1):27-42.

9. Son HJ, Kim SY, and Suh HS. Rapid systematic reviews. Journal of the Health Technology Assessment. 2013;1(1):75-85.

8. Suh HS, Hay JW, Johnson KA, and Doctor JN. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: Use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiology and Drug Safety. 2012;21(5):470-484 (2012.05).

7. Ahn J, Kim G, Suh HS, Sang Moo Lee. Social values and healthcare priority setting in Korea. Journal of Health Organization and Management. 2012;26(3):343-350.

6. Kang HY, Lim SJ,Suh HS, and Liew D. Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: a cost of illness study. BMC Public Health. 2011;11(1):646-656.

5. Suh HS, Lee D, Kim SY, Jee DH, and Kang HY. Direct-to-consumer advertising (DTCA) for prescription drugs: Consumers’ attitudes and preferences concerning its regulation in South Korea. Health Policy. 2011;101(3):260-268.

4. Suh HS, Song HJ, Choi JE, Jang EJ, Son HJ, Kim JS, Lee SM, and Choi DH. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: A systematic review and meta-analysis. International Journal of Technology Assessment in Health Care. 2011;27(1):11-22.

3. Choi HJ, Suh HS, Hahn S, Lee J, Park BJ, Lee SM, Kim HS, and Bae CW. Burden of illness for meconium aspiration syndromes and cost prediction related with surfactant therapy for meconium aspiration syndrome in Korea. Journal of the Korean Medical Association. 2011;54(5):549-556.

2. Park J, Ahn J, Suh HS, Park S, Hyun MK, Sung YK, Lee EK, and Kim Y. Willingness to pay for treatment for reducing risk of osteoporotic fractures. The Korean Journal of Health Economics and Policy. 2011;17(3):23-50.

1. Cho YG, Song HJ, Park BJ, and NECA-9 Lipid Lowering Agents Research Group. The comparison of guidelines for management of dyslipidemia and the appropriateness of them in Korea. Korean J Fam Med. 2010;31(3):171-181.

 

 

 

 

 

•  Books

 

 

· Pharmaceutical Related Laws and Regulations, 2020. Shinil Books, March 2020 (ISBN: 979-11-88847-75-4).

 

· Pharmaceutical Related Laws and Regulations, 2019. Shinil Books, February 2019 (ISBN: 979-11-88847-34-1).

 

· Pharmaceutical Related Laws and Regulations, 2018. Shinil Books, September 2018 (ISBN: 979-11-88847-19-8).

 

· Administrative and Managerial Pharmacy, 2nd Edition, Pan Mun Education, March 2018 (ISBN: 979-11-5943-096-1).

 

· Pharmaceutical Related Laws and Regulations, 2017. Shinil Books, September 2017 (ISBN: 979-11-8561-586-8).

 

· Economic Evaluation of Pharmacy Services, 1st Edition, Elsevier, October 2016 (ISBN: 978-0-12-803659-4).

 

· Pharmaceutical Related Laws and Regulations, 2016. Shinil Books, September 2016 (ISBN: 978-89-5702-451-5).

 

· Pharmaceutical Related Laws and Regulations, 2015. Shinil Books, September 2015 (ISBN: 978-89-5702-435-5).

 

· Pharmaceutical Related Laws and Regulations, 2014. Shinil Books, September 2014 (ISBN: 978-89-5702-402-7).

 

· Drug Information: A Guide for Pharmacists, 4th Edition., Shinil Books [Translated in Korean], 2014 (ISBN: 978-89-5702-384-6).

· NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention. National Evidence-based healthcare Collaborating Agency, 2011 (ISBN: 978-89-94581-59-0).

 

 

​

​

• Projects

· Global Pharmaceutical Company based in Korea. Cost-Effectiveness Model of OOO for the Treatment of OOO in Korea. 2020.12.14-2022.03.13 (PI).

· Global Pharmaceutical Company based in Korea. Economic Analysis of OOO for the Treatment of OOO in Korea. 2020.12.01-2022.11.30 (PI).

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Cost-Effectiveness Study of a Deeply-Inserted Acupotomy Applied to Hyeopcheok Points for Lumbosacral Neuropathy: A Prospective Comparative Effectiveness Trial. 2020.08.03-2024.12.31 (PI).

· National Research Foundation (Ministry of Science, ICT and Future Planning). Opioid abuse, risk assessment of opioid related harm, and economic benefit of introducing safe use strategy. 2020.06.01-2023.02.28 (PI).

· Ministry of Food and Drug Safety. 의약품 안전사고의 사회적 비용부담 체계 구축 및 운용방안 연구. 2020.05.28-2020.10.27 (PI).

· National Evidence based Healthcare Collaborating Agency (한국보건의료연구원). 환자중심 의료기술 최적화 연구사업 2차년도(2020년) 후보과제요약서(Topic Brief) 개발. 2020.05.04-2020.06.30 (PI).

· Ministry of Food and Drug Safety. A Study on Consumption of New and Illicit Drugs by Wastewater-Based Epidemiology: Establishment of monitoring system. 2020.04.08-2021.04.08 (PI).

· Global Pharmaceutical Company based in Korea. Disease Cost Analysis for Migraine in Korea. 2019.12.20-2020.12.19 (PI).

· Global Pharmaceutical Company based in Korea. National Health Insurance claims data analysis for Acute Myeloid Leukemia. 2019.12.19-2021.12.18 (PI).

· Global Pharmaceutical Company based in US. Estimating Short-Term and Long-Term Direct Economic Burden Associated with Osteoporotic Fracture in South Korea. 2019.11.20-2021.10.31 (PI).

· Global Pharmaceutical Company based in Korea. Budget Impact Analysis of Atorvastatin for Primary Prevention of Cardiovascular Disease in Type 2 Diabetes Mellitus. 2019.11.19-2022.11.18 (PI).

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Network Research on Clinical Course and Economic Outcomes of Incurable Eye Diseases Based on Extended Common Data Model. 2019.04.17-2021.12.31 (PI).

· Global Pharmaceutical Company based in Korea. Economic Analysis of OOO for the Treatment of OOO in Korea. 2018.12.22-2020.12.21 (PI).

· Global Pharmaceutical Company based in Korea. Cost-Effectiveness Analysis of OOO for the Treatment of OOO in Korea. 2017.06.01-2019.12.31 (PI).

· Global Pharmaceutical Company based in Korea. The Real World Evidence on Treatment Patterns, Effectiveness, and Safety in Nonvalvular Atrial Fibrillation Patients with Oral Anticoagulants in Korea. 2017.04.01-2020.12.31 (PI).

· Global Pharmaceutical Company based in Korea. Cost-Effectiveness Analysis of OOO for the Treatment of OOO in Korea. 2017.01.01-2019.12.31 (PI).

· Global Pharmaceutical Company based in US. Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in Hyperlipidemic Patients in South Korea. 2017.01.01-2019.12.31 (PI).

· Global Pharmaceutical Company based in Korea. Cost-Effectiveness Analysis of OOO for the Treatment of OOO in Korea. 2016.12.01-2020.12.31 (PI).

· Global Pharmaceutical Company based in Korea. Cost-Effectiveness Analysis of OOO for the Treatment of OOO in Korea. 2016.08.01-2018.12.30 (PI).

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Korean Medicine Clinical Practice Guidelines as Supportive Care for Breast Cancer (category: economic evaluation). 2016.08.01-2020.12.31.

· National Research Foundation (Ministry of Science, ICT and Future Planning). Drugs and patients’ behavior affecting Parkinsonism. 2016.07.01-2019.06.30 (PI).

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Korean medicine clinical practice guidelines for dysmenorrhea (category: economic evaluation). 2016.06.01-2020.12.31 (PI).

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Clinical Practice Guideline for Common Cold and Clinical Research for Evidence Development (category: economic evaluation). 2016.06.01-2020.12.31.

· Global Pharmaceutical Company based in US. Characteristics of Patients at High Risk for or with Cardiovascular Disease and Utilization Patterns of Lipid Lowering Therapies in South Korea. 2015.11.01-2017.10.31 (PI).

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Pharmaceutical care service model development for metabolic/chronic disease patients. 2014.11.01-2016.06.30.

· Korea Health Industry Development Institute (Ministry of Health and Welfare). Development of individualized process of drug use based on knowledgebase for appropriate medication therapy and evaluation of clinical utility. 2015.07.01-2016.06.30.

· Ministry of Food and Drug Safety. Development of education materials to ensure medication safety and prevent medication error. 2015.02.01-2015.11.30 (PI).

· Ministry of Food and Drug Safety. Development of training program of Pharmacovigilance and ADR reportingfor APEC countries. 2014.04.09-2014.10.09.